Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

29.42 +0.46 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics Inc

< Previous 1 2 3 4 Next >
Kymera Therapeutics Commences Initial-Stage Oncology Trials
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413. 
Via Benzinga
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Kymera Therapeutics Stock Is Gaining Wednesday
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell... 
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying
Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades. 
Via Benzinga
Why Kymera Therapeutics Shares Are Falling Today
 
Via Benzinga
Kymera Therapeutics: Q1 Earnings Insights
Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Executives Buy Around $141M Of 4 Stocks
Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
Via Benzinga
Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher
U.S. stocks traded slightly higher toward the end of trading on Tuesday. 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday. 
Via Benzinga
41 Stocks Moving In Tuesday's Mid-Day Session
Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Via Benzinga
Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET
Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474
JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58... 
Via Benzinga
Kymera Discloses New Development Cancer Program
Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to... 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to... 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.